S&P/ASX 200 to fall – ALD, CIM & CSL shares in focus
Drew Meredith, CFP
October 20, 2020
The S&P/ASX 200 (INDEXASX:XJO) is expected to slide when the
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (INDEXASX:XJO) is expected to slide when the
The CSL Limited (ASX:CSL) share price is up after the
CSL Limited (ASX:CSL) has continued to be in the top
CSL Limited (ASX:CSL) has signed an agreement with the Australian
Share buy-backs have been used by many companies on the
Are big 4 ASX bank shares ‘risky’? Let’s take a
Top performing fund manager, Hyperion Asset Management, recently released an
CSL Limited (ASX:CSL) has revealed that it will manufacture and
In the second installment of our ASX Reporting Season Results
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.